orlistat vs glp 1 Lilly orforglipron oral GLP-1 phase 3 weight loss trial Orforglipron and Its Unique Delivery

Important safety information: Tirzepatide has a boxed warning for thyroid C-cell tumors and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2

Unger JM, Till C, Tangen CM, Hershman DL, Goodman PJ, LeBlanc M, Barlow WE, Vaidya R, Minasian LM, Parnes HL, Thompson IM

Wed, Jul 22, 2026 0 Comments Audio By Carbonatix By Nancy Lapid July 22 (Reuters) The risk of hair loss in patients taking GLP-1 drugs for obesity or diabetes, while low, is higher than with other diabetes drugs, new studies suggest

In late-stage trials, people taking retatrutide have lost up to 28% of their body weight over a years time, the most impressive results seen for any weight loss drug to date

This is why many compounded medications come in amber-colored vials or are recommended to be kept in their original box until the moment of use